With all the chatter about health care reform coming out of Washington, now may be a great time to consider health care-related investments.
Most investors look to big pharmaceutical companies for health care exposure. That was the old way of profiting from the medical arena. While these stocks are usually considered blue chips, they face a toxic combination of competition from generic drug makers and their own empty new-drug pipelines. Think about it: When was the last time Merck (MRK) or Pfizer (PFE) released a true blockbuster drug? Answer: It’s been a while.